Table 4.
Prognostic factors in women with breast cancer.
| Variable | HRa | 95% CI | p-value | HRc | 95% CI | p-value |
|---|---|---|---|---|---|---|
| Clinical stage | ||||||
| I | 1.0b | 1.0b | ||||
| IIA | 1.1 | 0.5-2.4 | 0.728 | 1.1 | 0.5-2.5 | 0.718 |
| IIB | 1.5 | 0.8-3.1 | 0.243 | 1.4 | 0.7-2.9 | 0.311 |
| IIIA | 3.9 | 2.0-7.5 | <0.001 | 3.9 | 1.9-7.6 | <0.001 |
| IIIB | 6.5 | 3.3-12.6 | <0.001 | 6.7 | 3.4-13.2 | <0.001 |
| Delayed of initial treatment | ||||||
| <45 days | 1.0‡ | 1.0b | ||||
| ≥45 days | 1.6 | 1.1-2.2 | 0.006 | 1.8 | 1.4-2.6 | <0.001 |
| Lymphovascular invasion | ||||||
| Absent | 1.0b | 1.0b | ||||
| Present | 1.2 | 0.8-1.7 | 0.361 | 1.4 | 0.90-2.0 | 0.090 |
| Molecular classification | ||||||
| Luminal A | 1.0b | 1.0b | ||||
| Luminal B | 1.4 | 0.8-2.7 | 0.247 | 1.7 | 0.9-3.1 | 0.106 |
| Her2Neu | 1.3 | 0.8-2.1 | 0.319 | 1.3 | 0.8-2.1 | 0.361 |
| Triple Negative | 1.9 | 1.4-2.3 | <0.001 | 1.7 | 1.3-2.4 | <0.001 |
a
Raw hazard ratio.
b
Reference Category.
c
Adjusted hazard ratio for clinical stage, lymphovascular invasion, categories of delay in treatment and molecular classification.